Neumora Therapeutics (NMRA) Projected to Post Earnings on Wednesday

Neumora Therapeutics (NASDAQ:NMRA - Get Free Report) is projected to announce its Q2 2025 earnings results after the market closes on Wednesday, August 6th. Analysts expect the company to announce earnings of ($0.38) per share for the quarter.

Neumora Therapeutics (NASDAQ:NMRA - Get Free Report) last posted its quarterly earnings results on Monday, May 12th. The company reported ($0.42) earnings per share for the quarter, missing analysts' consensus estimates of ($0.40) by ($0.02). On average, analysts expect Neumora Therapeutics to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Neumora Therapeutics Price Performance

Shares of NMRA traded down $0.40 during midday trading on Friday, reaching $1.56. 2,110,043 shares of the stock were exchanged, compared to its average volume of 2,197,878. The business's 50-day moving average price is $1.15 and its 200 day moving average price is $1.21. Neumora Therapeutics has a twelve month low of $0.61 and a twelve month high of $17.19. The company has a market capitalization of $252.33 million, a price-to-earnings ratio of -0.97 and a beta of 2.87.

Wall Street Analyst Weigh In

A number of research analysts have recently issued reports on NMRA shares. Mizuho boosted their target price on Neumora Therapeutics from $4.00 to $5.00 and gave the company an "outperform" rating in a report on Wednesday, July 16th. Needham & Company LLC reaffirmed a "buy" rating and issued a $5.00 price objective on shares of Neumora Therapeutics in a report on Tuesday, May 13th. One research analyst has rated the stock with a sell rating, five have given a hold rating and three have assigned a buy rating to the company's stock. According to MarketBeat.com, the company has a consensus rating of "Hold" and an average price target of $7.14.

Institutional Investors Weigh In On Neumora Therapeutics

A hedge fund recently raised its stake in Neumora Therapeutics stock. Invesco Ltd. raised its holdings in shares of Neumora Therapeutics, Inc. (NASDAQ:NMRA - Free Report) by 151.1% in the first quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 123,655 shares of the company's stock after buying an additional 74,406 shares during the period. Invesco Ltd. owned about 0.08% of Neumora Therapeutics worth $124,000 as of its most recent SEC filing. Institutional investors own 47.65% of the company's stock.

About Neumora Therapeutics

Neumora Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder.